These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 29158144)
61. In vitro activity of ceftolozane/tazobactam versus antimicrobial non-susceptible Pseudomonas aeruginosa clinical isolates including MDR and XDR isolates obtained from across Canada as part of the CANWARD study, 2008-16. Walkty A; Adam H; Baxter M; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG J Antimicrob Chemother; 2018 Mar; 73(3):703-708. PubMed ID: 29244121 [TBL] [Abstract][Full Text] [Related]
62. In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem. Bretonnière C; Boutoille D; Caillon J; Desessard C; Guitton C; Potel G; Jacqueline C Int J Antimicrob Agents; 2014 Sep; 44(3):218-21. PubMed ID: 25108877 [TBL] [Abstract][Full Text] [Related]
63. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Liscio JL; Mahoney MV; Hirsch EB Int J Antimicrob Agents; 2015 Sep; 46(3):266-71. PubMed ID: 26143591 [TBL] [Abstract][Full Text] [Related]
64. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related]
65. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands. Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088 [TBL] [Abstract][Full Text] [Related]
69. Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa. Rodríguez-Núñez O; Ripa M; Morata L; de la Calle C; Cardozo C; Fehér C; Pellicé M; Valcárcel A; Puerta-Alcalde P; Marco F; García-Vidal C; Del Río A; Soriano A; Martínez-Martínez JA J Glob Antimicrob Resist; 2018 Dec; 15():136-139. PubMed ID: 30036695 [TBL] [Abstract][Full Text] [Related]
70. Ceftolozane-tazobactam resistance induced in vivo during the treatment of MDR Pseudomonas aeruginosa pneumonia. Plant AJ; Dunn A; Porter RJ Expert Rev Anti Infect Ther; 2018 May; 16(5):367-368. PubMed ID: 29727213 [No Abstract] [Full Text] [Related]
71. The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs. Borgatta B; Gattarello S; Mazo CA; Imbiscuso AT; Larrosa MN; Lujàn M; Rello J Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2155-2163. PubMed ID: 28624864 [TBL] [Abstract][Full Text] [Related]
72. Profile of ceftolozane/tazobactam and its potential in the treatment of complicated intra-abdominal infections. Skalweit MJ Drug Des Devel Ther; 2015; 9():2919-25. PubMed ID: 26082619 [TBL] [Abstract][Full Text] [Related]
73. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Farrell DJ; Sader HS; Flamm RK; Jones RN Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078 [TBL] [Abstract][Full Text] [Related]
74. Efficacy, pharmacokinetic and pharmacodynamic profile of ceftolozane + tazobactam in the treatment of complicated urinary tract infections. Wagenlehner FM; Alidjanov JF Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):959-66. PubMed ID: 27327964 [TBL] [Abstract][Full Text] [Related]
75. Ceftolozane/tazobactam: place in therapy. Giacobbe DR; Bassetti M; De Rosa FG; Del Bono V; Grossi PA; Menichetti F; Pea F; Rossolini GM; Tumbarello M; Viale P; Viscoli C; Expert Rev Anti Infect Ther; 2018 Apr; 16(4):307-320. PubMed ID: 29493397 [TBL] [Abstract][Full Text] [Related]
76. Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa. Monogue ML; Nicolau DP J Antimicrob Chemother; 2018 Apr; 73(4):942-952. PubMed ID: 29272436 [TBL] [Abstract][Full Text] [Related]
77. Ceftolozane-tazobactam: A new-generation cephalosporin. Cluck D; Lewis P; Stayer B; Spivey J; Moorman J Am J Health Syst Pharm; 2015 Dec; 72(24):2135-46. PubMed ID: 26637512 [TBL] [Abstract][Full Text] [Related]
78. [Utilization study in real clinical practice of ceftolozane/tazobactam vs aminoglycosides and/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa]. Pinilla-Rello A; Huarte-Lacunza R; Magallón-Martínez A; Cazorla-Poderoso L; Pereira-Blanco O; Pérez-Moreno M; Larrodé-Leciñena I; Martínez-Álvarez RM; López-Calleja AI Rev Esp Quimioter; 2021 Oct; 34(5):441-449. PubMed ID: 34154319 [TBL] [Abstract][Full Text] [Related]
79. Clinical efficacy of piperacillin/tazobactam in the treatment of complicated skin and soft tissue infections. Takimoto K; Wang Q; Suzuki D; Katayama M; Hayashi Y Expert Opin Pharmacother; 2017 Jul; 18(10):1027-1034. PubMed ID: 28627952 [TBL] [Abstract][Full Text] [Related]
80. Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program. Stewart A; Roberts JA; Wallis SC; Allworth AM; Legg A; McCarthy KL Int J Antimicrob Agents; 2018 Jun; 51(6):941-942. PubMed ID: 29471023 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]